Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis
•COVID-19 was found to be associated with autoantibodies against type I interferons (IFNs).•The most common subtypes were anti-IFN-α (89%) and anti-IFN-ω (77%).•The prevalence of anti-IFN-I autoantibodies was 10% in patients with severe COVID-19.•Anti-IFN-I autoantibodies were more common in male pa...
Saved in:
| Published in | International journal of infectious diseases Vol. 130; pp. 147 - 152 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Canada
Elsevier Ltd
01.05.2023
The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1201-9712 1878-3511 1878-3511 |
| DOI | 10.1016/j.ijid.2023.03.011 |
Cover
| Abstract | •COVID-19 was found to be associated with autoantibodies against type I interferons (IFNs).•The most common subtypes were anti-IFN-α (89%) and anti-IFN-ω (77%).•The prevalence of anti-IFN-I autoantibodies was 10% in patients with severe COVID-19.•Anti-IFN-I autoantibodies were more common in male patients.
In this study, we aimed to study the rate of autoantibodies against type I interferons (IFNs) in patients with COVID-19 and analyze its dependence on severity of infection and some other variables.
A systemic review with the search terms: “COVID-19” or “SARS-CoV-2” and “autoantibodies” or “autoantibody” and “IFN” or “interferon” for the period 20 December 2019 to 15 August 2022 was carried out using PubMed, Embase, Cochrane, and Web of Science. R 4.2.1 software was used for meta-analysis of the published results. Pooled risk ratios and 95% confidence intervals (CIs) were calculated.
We identified eight studies involving 7729 patients, of whom 5097 (66%) had severe COVID-19 and 2632 (34%) had mild or moderate symptoms. The positive rate of anti-type-I-IFN-autoantibodies in the total dataset was 5% (95% CI, 3-8%), but reached 10% (95% CI, 7-14%) in those with severe infection. The most common subtypes were anti-IFN-α (89%) and anti-IFN-ω (77%). The overall prevalence in male patients was 5% (95% CI, 4-6%), and in female patients 2% (95% CI, 1-3%).
Severe COVID-19 is associated with high rates of autoantibodies against type-I-IFN and more so in male than female patients. |
|---|---|
| AbstractList | Objectives: In this study, we aimed to study the rate of autoantibodies against type I interferons (IFNs) in patients with COVID-19 and analyze its dependence on severity of infection and some other variables. Methods: A systemic review with the search terms: “COVID-19” or “SARS-CoV-2” and “autoantibodies” or “autoantibody” and “IFN” or “interferon” for the period 20 December 2019 to 15 August 2022 was carried out using PubMed, Embase, Cochrane, and Web of Science. R 4.2.1 software was used for meta-analysis of the published results. Pooled risk ratios and 95% confidence intervals (CIs) were calculated. Results: We identified eight studies involving 7729 patients, of whom 5097 (66%) had severe COVID-19 and 2632 (34%) had mild or moderate symptoms. The positive rate of anti-type-I-IFN-autoantibodies in the total dataset was 5% (95% CI, 3-8%), but reached 10% (95% CI, 7-14%) in those with severe infection. The most common subtypes were anti-IFN-α (89%) and anti-IFN-ω (77%). The overall prevalence in male patients was 5% (95% CI, 4-6%), and in female patients 2% (95% CI, 1-3%). Conclusion: Severe COVID-19 is associated with high rates of autoantibodies against type-I-IFN and more so in male than female patients. •COVID-19 was found to be associated with autoantibodies against type I interferons (IFNs).•The most common subtypes were anti-IFN-α (89%) and anti-IFN-ω (77%).•The prevalence of anti-IFN-I autoantibodies was 10% in patients with severe COVID-19.•Anti-IFN-I autoantibodies were more common in male patients. In this study, we aimed to study the rate of autoantibodies against type I interferons (IFNs) in patients with COVID-19 and analyze its dependence on severity of infection and some other variables. A systemic review with the search terms: “COVID-19” or “SARS-CoV-2” and “autoantibodies” or “autoantibody” and “IFN” or “interferon” for the period 20 December 2019 to 15 August 2022 was carried out using PubMed, Embase, Cochrane, and Web of Science. R 4.2.1 software was used for meta-analysis of the published results. Pooled risk ratios and 95% confidence intervals (CIs) were calculated. We identified eight studies involving 7729 patients, of whom 5097 (66%) had severe COVID-19 and 2632 (34%) had mild or moderate symptoms. The positive rate of anti-type-I-IFN-autoantibodies in the total dataset was 5% (95% CI, 3-8%), but reached 10% (95% CI, 7-14%) in those with severe infection. The most common subtypes were anti-IFN-α (89%) and anti-IFN-ω (77%). The overall prevalence in male patients was 5% (95% CI, 4-6%), and in female patients 2% (95% CI, 1-3%). Severe COVID-19 is associated with high rates of autoantibodies against type-I-IFN and more so in male than female patients. In this study, we aimed to study the rate of autoantibodies against type I interferons (IFNs) in patients with COVID-19 and analyze its dependence on severity of infection and some other variables. A systemic review with the search terms: "COVID-19" or "SARS-CoV-2" and "autoantibodies" or "autoantibody" and "IFN" or "interferon" for the period 20 December 2019 to 15 August 2022 was carried out using PubMed, Embase, Cochrane, and Web of Science. R 4.2.1 software was used for meta-analysis of the published results. Pooled risk ratios and 95% confidence intervals (CIs) were calculated. We identified eight studies involving 7729 patients, of whom 5097 (66%) had severe COVID-19 and 2632 (34%) had mild or moderate symptoms. The positive rate of anti-type-I-IFN-autoantibodies in the total dataset was 5% (95% CI, 3-8%), but reached 10% (95% CI, 7-14%) in those with severe infection. The most common subtypes were anti-IFN-α (89%) and anti-IFN-ω (77%). The overall prevalence in male patients was 5% (95% CI, 4-6%), and in female patients 2% (95% CI, 1-3%). Severe COVID-19 is associated with high rates of autoantibodies against type-I-IFN and more so in male than female patients. In this study, we aimed to study the rate of autoantibodies against type I interferons (IFNs) in patients with COVID-19 and analyze its dependence on severity of infection and some other variables.OBJECTIVESIn this study, we aimed to study the rate of autoantibodies against type I interferons (IFNs) in patients with COVID-19 and analyze its dependence on severity of infection and some other variables.A systemic review with the search terms: "COVID-19" or "SARS-CoV-2" and "autoantibodies" or "autoantibody" and "IFN" or "interferon" for the period 20 December 2019 to 15 August 2022 was carried out using PubMed, Embase, Cochrane, and Web of Science. R 4.2.1 software was used for meta-analysis of the published results. Pooled risk ratios and 95% confidence intervals (CIs) were calculated.METHODSA systemic review with the search terms: "COVID-19" or "SARS-CoV-2" and "autoantibodies" or "autoantibody" and "IFN" or "interferon" for the period 20 December 2019 to 15 August 2022 was carried out using PubMed, Embase, Cochrane, and Web of Science. R 4.2.1 software was used for meta-analysis of the published results. Pooled risk ratios and 95% confidence intervals (CIs) were calculated.We identified eight studies involving 7729 patients, of whom 5097 (66%) had severe COVID-19 and 2632 (34%) had mild or moderate symptoms. The positive rate of anti-type-I-IFN-autoantibodies in the total dataset was 5% (95% CI, 3-8%), but reached 10% (95% CI, 7-14%) in those with severe infection. The most common subtypes were anti-IFN-α (89%) and anti-IFN-ω (77%). The overall prevalence in male patients was 5% (95% CI, 4-6%), and in female patients 2% (95% CI, 1-3%).RESULTSWe identified eight studies involving 7729 patients, of whom 5097 (66%) had severe COVID-19 and 2632 (34%) had mild or moderate symptoms. The positive rate of anti-type-I-IFN-autoantibodies in the total dataset was 5% (95% CI, 3-8%), but reached 10% (95% CI, 7-14%) in those with severe infection. The most common subtypes were anti-IFN-α (89%) and anti-IFN-ω (77%). The overall prevalence in male patients was 5% (95% CI, 4-6%), and in female patients 2% (95% CI, 1-3%).Severe COVID-19 is associated with high rates of autoantibodies against type-I-IFN and more so in male than female patients.CONCLUSIONSevere COVID-19 is associated with high rates of autoantibodies against type-I-IFN and more so in male than female patients. |
| Author | Xu, Jing Tang, Qi Li, Hongmei Bergquist, Robert Qin, Zhiqiang Jiang, Honglin Wang, Xi |
| Author_xml | – sequence: 1 givenname: Xi surname: Wang fullname: Wang, Xi organization: National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research), Shanghai, People's Republic of China – sequence: 2 givenname: Qi surname: Tang fullname: Tang, Qi organization: National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research), Shanghai, People's Republic of China – sequence: 3 givenname: Hongmei surname: Li fullname: Li, Hongmei organization: National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research), Shanghai, People's Republic of China – sequence: 4 givenname: Honglin orcidid: 0000-0001-8815-0780 surname: Jiang fullname: Jiang, Honglin organization: Fudan University School of Public Health, Shanghai, People's Republic of China – sequence: 5 givenname: Jing surname: Xu fullname: Xu, Jing organization: National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research), Shanghai, People's Republic of China – sequence: 6 givenname: Robert surname: Bergquist fullname: Bergquist, Robert organization: Ingerod, Brastad, Sweden (formerly at the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) – sequence: 7 givenname: Zhiqiang orcidid: 0000-0002-1130-4689 surname: Qin fullname: Qin, Zhiqiang email: qinzq@nipd.chinacdc.cn organization: National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research), Shanghai, People's Republic of China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36907547$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUk1vEzEQXaEi-gF_gAPaI5cN_ljvriskFIWvSJV6Aa7WrD0ODhs72E5R_j0OaRHtoUgjeTSe995o3pxXJz54rKqXlMwood2b9cytnZkxwviMlKD0SXVGh35ouKD0pOSM0Eb2lJ1W5ymtCSFt1w3PqlPeSdKLtj-r7HyXA_jsxmAcphpW4HzKdd5vsV7WzmeMFmPwqeT14vrb8n1DZckt6uyCv6znddqnjBvITtcRbxz-qsGbeoMZGvAw7ZNLz6unFqaEL27fi-rrxw9fFp-bq-tPy8X8qtGi57kZrLaWaGZhJJ0xXQtDp7EVLXRcMN73goxCSsmIBSEpjFoSS3VvsBRaIflFtTzymgBrtY1uA3GvAjj1pxDiSkEsg06odMs1MDBmJKxtSSeF7DQVI7GjhJFD4Xp35Nruxg0ajT5HmO6R3v_x7rtahRtFy6LFwIfC8PqWIYafO0xZbVzSOE3gMeySYv3QFacEb0vrq3_F_qrcOVUahmODjiGliFZpl-FgQdF2UxFVh6NQa3U4CnU4CkVKUFqg7AH0jv1R0NsjCItdxdSoknboNRoXi_Vln-5x-OUDuJ6cdxqmH7j_H_g3ZqPk0Q |
| CitedBy_id | crossref_primary_10_1016_j_jtauto_2023_100219 crossref_primary_10_1111_sji_13344 crossref_primary_10_1007_s10875_023_01606_4 crossref_primary_10_1172_jci_insight_180750 crossref_primary_10_3390_v15051215 crossref_primary_10_47360_1995_4484_2023_397_420 crossref_primary_10_1007_s00393_023_01455_x crossref_primary_10_1007_s10096_023_04688_5 crossref_primary_10_1038_s41541_024_00829_9 crossref_primary_10_1089_jir_2023_0087 crossref_primary_10_1016_j_clicom_2024_11_001 crossref_primary_10_1016_j_ymthe_2024_04_019 crossref_primary_10_3390_bios14030130 crossref_primary_10_17816_CI636474 |
| Cites_doi | 10.3389/fimmu.2021.705772 10.3390/cells10123592 10.1111/all.15302 10.1126/science.abc6027 10.1111/cts.12953 10.1016/j.autrev.2020.102743 10.1126/scitranslmed.abh2624 10.1038/s41586-021-03631-y 10.1111/imcb.12495 10.1016/j.jhep.2021.04.003 10.3390/ijms22168965 10.1007/s10875-022-01252-2 10.1002/eji.202249824 10.1016/j.immuni.2020.05.002 10.1016/S0140-6736(20)30183-5 10.1007/s10875-021-01203-3 10.1002/cti2.1327 10.1038/s41579-020-00459-7 10.1172/JCI150867 10.1126/science.abd4585 10.1093/ofid/ofab466.649 10.1007/s00439-020-02180-0 10.1002/iid3.109 10.1093/cid/ciab1002 10.1126/sciimmunol.abl4340 10.1007/s10875-022-01308-3 10.1016/j.comppsych.2015.05.001 |
| ContentType | Journal Article |
| Copyright | 2023 The Author(s) Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023 |
| Copyright_xml | – notice: 2023 The Author(s) – notice: Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. – notice: 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1016/j.ijid.2023.03.011 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1878-3511 |
| EndPage | 152 |
| ExternalDocumentID | oai_doaj_org_article_c43ca2addb0244069596c15b0fb9ab3a PMC10005838 36907547 10_1016_j_ijid_2023_03_011 S1201971223000875 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GroupedDBID | --- --K .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 29J 3O- 4.4 457 4G. 53G 5GY 5VS 7-5 71M 7X7 88E 8C1 8FI 8FJ 8FQ 8R4 8R5 AAEDW AAFWJ AAIKJ AALRI AAQFI AAQXK AARKO AAXUO AAYWO ABBQC ABFRF ABMAC ABUWG ABWVN ACGFO ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFJKZ AFKRA AFPKN AFPUW AFRHN AFTJW AGEKW AGHFR AGQPQ AGYEJ AHMBA AIGII AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP ASPBG AVWKF AZFZN BAWUL BCNDV BENPR BPHCQ BR6 BVXVI CCPQU CS3 DIK DU5 DWQXO E3Z EBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FNPLU FYUFA G-Q GBLVA GROUPED_DOAJ GX1 HMCUK HVGLF HZ~ IHE IXB J1W KQ8 M1P M3C M3G M41 MO0 N9A O-L O9- OD- OK1 OO. OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO Q2X Q38 QTD R2- ROL RPZ RWL RXW SDF SDG SEL SES SEW SSZ TAE UKHRP UNMZH Z5R 0SF 3V. 6I. AACTN AAFTH ABVKL AFCTW NCXOZ RIG AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM 7X8 ~HD 5PM |
| ID | FETCH-LOGICAL-c573t-8fcff0c2fab06dd64a86ce454a635237750b599920fa591abc90f1c7de0fa4593 |
| IEDL.DBID | DOA |
| ISSN | 1201-9712 1878-3511 |
| IngestDate | Wed Aug 27 01:17:55 EDT 2025 Thu Aug 21 18:37:40 EDT 2025 Sun Sep 28 11:00:09 EDT 2025 Wed Feb 19 02:24:12 EST 2025 Tue Jul 01 04:30:16 EDT 2025 Thu Apr 24 23:13:24 EDT 2025 Fri Feb 23 02:37:32 EST 2024 Tue Aug 26 16:32:08 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 Anti-type-I-IFN-autoantibodies Meta-analysis |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c573t-8fcff0c2fab06dd64a86ce454a635237750b599920fa591abc90f1c7de0fa4593 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-1130-4689 0000-0001-8815-0780 |
| OpenAccessLink | https://doaj.org/article/c43ca2addb0244069596c15b0fb9ab3a |
| PMID | 36907547 |
| PQID | 2786511534 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_c43ca2addb0244069596c15b0fb9ab3a pubmedcentral_primary_oai_pubmedcentral_nih_gov_10005838 proquest_miscellaneous_2786511534 pubmed_primary_36907547 crossref_citationtrail_10_1016_j_ijid_2023_03_011 crossref_primary_10_1016_j_ijid_2023_03_011 elsevier_sciencedirect_doi_10_1016_j_ijid_2023_03_011 elsevier_clinicalkey_doi_10_1016_j_ijid_2023_03_011 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-05-01 |
| PublicationDateYYYYMMDD | 2023-05-01 |
| PublicationDate_xml | – month: 05 year: 2023 text: 2023-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Canada |
| PublicationPlace_xml | – name: Canada |
| PublicationTitle | International journal of infectious diseases |
| PublicationTitleAlternate | Int J Infect Dis |
| PublicationYear | 2023 |
| Publisher | Elsevier Ltd The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases – name: Elsevier |
| References | Yee, Tso, Shaw (bib0014) 2021; 8 Wang, Mao, Klein (bib0004) 2021; 595 Goncalves, Mezidi, Bastard (bib0016) 2021; 10 Sacchi, Tamiazzo, Stobbione (bib0018) 2021; 14 Gracia-Ramos, Martin-Nares, Hernández-Molina (bib0028) 2021; 10 World Health Organization. Director General's opening remarks at the media briefing on COVID-19 Moody, Wilson, Flanagan, Jaworowski, Plebanski (bib0017) 2021; 22 van der Wijst, Vazquez, Hartoularos (bib0009) 2021; 13 Eto, Nukui, Tsumura (bib0013) 2022; 42 Bril, Al Diffalha, Dean (bib0030) 2021; 75 Huang, Wang, Li (bib0002) 2020; 395 Kärner, Pihlap, Ranki (bib0021) 2016; 4 Vabret, Britton, Gruber (bib0005) 2020; 52 Xiao, Miller, Zheng (bib0025) 2021; 20 2020 [accessed 22 November 2022]. Meisel, Akbil, Meyer (bib0024) 2021; 131 Frasca, Scordio, Santinelli (bib0011) 2022; 52 Ramasamy, Subbian (bib0006) 2021; 34 Bastard, Gervais, Le Voyer (bib0015) 2021; 6 Hadjadj, Yatim, Barnabei (bib0023) 2020; 369 Karami Fath, Jahangiri, Ganji (bib0029) 2021; 12 Zhang, Bastard, Bolze (bib0022) 2020; 1 Abers, Rosen, Delmonte (bib0008) 2021; 99 Ku, Chi, von Bernuth (bib0020) 2020; 139 Hu, Guo, Zhou, Shi (bib0003) 2021; 19 Taeschler, Cervia, Zurbuchen (bib0019) 2022; 77 Akbil, Meyer, Stubbemann (bib0012) 2022; 42 Bastard, Rosen, Zhang (bib0007) 2020; 370 Chauvineau-Grenier, Bastard, Servajean (bib0026) 2022; 42 Hu, Dong, Chen (bib0010) 2015; 61 Shaw, Rosen, Cheng (bib0027) 2022; 75 Wang (10.1016/j.ijid.2023.03.011_bib0004) 2021; 595 Bastard (10.1016/j.ijid.2023.03.011_bib0007) 2020; 370 Frasca (10.1016/j.ijid.2023.03.011_bib0011) 2022; 52 Karami Fath (10.1016/j.ijid.2023.03.011_bib0029) 2021; 12 van der Wijst (10.1016/j.ijid.2023.03.011_bib0009) 2021; 13 Abers (10.1016/j.ijid.2023.03.011_bib0008) 2021; 99 Shaw (10.1016/j.ijid.2023.03.011_bib0027) 2022; 75 Kärner (10.1016/j.ijid.2023.03.011_bib0021) 2016; 4 Eto (10.1016/j.ijid.2023.03.011_bib0013) 2022; 42 Yee (10.1016/j.ijid.2023.03.011_bib0014) 2021; 8 Hadjadj (10.1016/j.ijid.2023.03.011_bib0023) 2020; 369 Hu (10.1016/j.ijid.2023.03.011_bib0010) 2015; 61 Akbil (10.1016/j.ijid.2023.03.011_bib0012) 2022; 42 Bastard (10.1016/j.ijid.2023.03.011_bib0015) 2021; 6 Chauvineau-Grenier (10.1016/j.ijid.2023.03.011_bib0026) 2022; 42 Taeschler (10.1016/j.ijid.2023.03.011_bib0019) 2022; 77 Ramasamy (10.1016/j.ijid.2023.03.011_bib0006) 2021; 34 Gracia-Ramos (10.1016/j.ijid.2023.03.011_bib0028) 2021; 10 Bril (10.1016/j.ijid.2023.03.011_bib0030) 2021; 75 Meisel (10.1016/j.ijid.2023.03.011_bib0024) 2021; 131 10.1016/j.ijid.2023.03.011_bib0001 Sacchi (10.1016/j.ijid.2023.03.011_bib0018) 2021; 14 Huang (10.1016/j.ijid.2023.03.011_bib0002) 2020; 395 Goncalves (10.1016/j.ijid.2023.03.011_bib0016) 2021; 10 Moody (10.1016/j.ijid.2023.03.011_bib0017) 2021; 22 Zhang (10.1016/j.ijid.2023.03.011_bib0022) 2020; 1 Xiao (10.1016/j.ijid.2023.03.011_bib0025) 2021; 20 Hu (10.1016/j.ijid.2023.03.011_bib0003) 2021; 19 Ku (10.1016/j.ijid.2023.03.011_bib0020) 2020; 139 Vabret (10.1016/j.ijid.2023.03.011_bib0005) 2020; 52 |
| References_xml | – volume: 42 start-page: 1111 year: 2022 end-page: 1129 ident: bib0012 article-title: Early and rapid identification of COVID-19 patients with neutralizing type I interferon auto-antibodies publication-title: J Clin Immunol – volume: 42 start-page: 1360 year: 2022 end-page: 1370 ident: bib0013 article-title: Neutralizing Type I interferon autoantibodies in Japanese patients with severe COVID-19 publication-title: J Clin Immunol – reference: ; 2020 [accessed 22 November 2022]. – volume: 52 start-page: 910 year: 2020 end-page: 941 ident: bib0005 article-title: Immunology of COVID-19: current state of the science publication-title: Immunity – volume: 52 start-page: 1120 year: 2022 end-page: 1128 ident: bib0011 article-title: Anti-IFN-α/-ω neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity publication-title: Eur J Immunol – volume: 20 year: 2021 ident: bib0025 article-title: An updated advance of autoantibodies in autoimmune diseases publication-title: Autoimmun Rev – volume: 131 year: 2021 ident: bib0024 article-title: Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1 publication-title: J Clin Invest – volume: 8 year: 2021 ident: bib0014 article-title: Type-I interferon autoantibodies are detected in those with critical COVID-19, including a young female patient publication-title: Open Forum Infect Dis – volume: 75 start-page: e1192 year: 2022 end-page: e1194 ident: bib0027 article-title: Temporal dynamics of anti-type 1 interferon autoantibodies in patients with coronavirus disease 2019 publication-title: Clin Infect Dis – volume: 14 start-page: 898 year: 2021 end-page: 907 ident: bib0018 article-title: SARS-CoV-2 infection as a trigger of autoimmune response publication-title: Clin Transl Sci – volume: 61 start-page: 78 year: 2015 end-page: 89 ident: bib0010 article-title: Prevalence of suicide attempts among Chinese adolescents: a meta-analysis of cross-sectional studies publication-title: Compr Psychiatry – volume: 22 start-page: 8965 year: 2021 ident: bib0017 article-title: Adaptive immunity and the risk of autoreactivity in COVID-19 publication-title: Int J Mol Sci – volume: 10 start-page: e1327 year: 2021 ident: bib0016 article-title: Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients publication-title: Clin Transl Immunology – volume: 77 start-page: 2415 year: 2022 end-page: 2430 ident: bib0019 article-title: Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures publication-title: Allergy – volume: 99 start-page: 917 year: 2021 end-page: 921 ident: bib0008 article-title: Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19 publication-title: Immunol Cell Biol – volume: 369 start-page: 718 year: 2020 end-page: 724 ident: bib0023 article-title: Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients publication-title: Science – volume: 12 year: 2021 ident: bib0029 article-title: SARS-CoV-2 proteome harbors peptides which are able to trigger autoimmunity responses: implications for infection, vaccination, and population coverage publication-title: Front Immunol – volume: 595 start-page: 283 year: 2021 end-page: 288 ident: bib0004 article-title: Diverse functional autoantibodies in patients with COVID-19 publication-title: Nature – volume: 6 start-page: eabl4340 year: 2021 ident: bib0015 article-title: Autoantibodies neutralizing type I IFNs are present in ∼4% of uninfected individuals over 70 years old and account for ∼20% of COVID-19 deaths publication-title: Sci Immunol – volume: 1 start-page: 14 year: 2020 end-page: 20 ident: bib0022 article-title: Life-threatening COVID-19: defective interferons unleash excessive inflammation publication-title: Med (N Y) – volume: 370 start-page: eabd4585 year: 2020 ident: bib0007 article-title: Autoantibodies against type I IFNs in patients with life-threatening COVID-19 publication-title: Science – volume: 42 start-page: 459 year: 2022 end-page: 470 ident: bib0026 article-title: Autoantibodies neutralizing Type I interferons in 20% of COVID-19 deaths in a French hospital publication-title: J Clin Immunol – volume: 139 start-page: 783 year: 2020 end-page: 794 ident: bib0020 article-title: Autoantibodies against cytokines: phenocopies of primary immunodeficiencies? publication-title: Hum Genet – volume: 4 start-page: 235 year: 2016 end-page: 243 ident: bib0021 article-title: IL-6-specific autoantibodies among APECED and thymoma patients publication-title: Immun Inflamm Dis – volume: 395 start-page: 497 year: 2020 end-page: 506 ident: bib0002 article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China publication-title: Lancet – volume: 13 start-page: eabh2624 year: 2021 ident: bib0009 article-title: Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19 publication-title: Sci Transl Med – reference: World Health Organization. Director General's opening remarks at the media briefing on COVID-19, – volume: 75 start-page: 222 year: 2021 end-page: 224 ident: bib0030 article-title: Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty? publication-title: J Hepatol – volume: 10 start-page: 3592 year: 2021 ident: bib0028 article-title: New onset of autoimmune diseases following COVID-19 diagnosis publication-title: Cells – volume: 19 start-page: 141 year: 2021 end-page: 154 ident: bib0003 article-title: Characteristics of SARS-CoV-2 and COVID-19 publication-title: Nat Rev Microbiol – volume: 34 year: 2021 ident: bib0006 article-title: Critical Determinants of cytokine Storm and Type I interferon Response in COVID-19 pathogenesis publication-title: Clin Microbiol Rev – volume: 12 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0029 article-title: SARS-CoV-2 proteome harbors peptides which are able to trigger autoimmunity responses: implications for infection, vaccination, and population coverage publication-title: Front Immunol doi: 10.3389/fimmu.2021.705772 – volume: 34 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0006 article-title: Critical Determinants of cytokine Storm and Type I interferon Response in COVID-19 pathogenesis publication-title: Clin Microbiol Rev – volume: 1 start-page: 14 year: 2020 ident: 10.1016/j.ijid.2023.03.011_bib0022 article-title: Life-threatening COVID-19: defective interferons unleash excessive inflammation publication-title: Med (N Y) – volume: 10 start-page: 3592 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0028 article-title: New onset of autoimmune diseases following COVID-19 diagnosis publication-title: Cells doi: 10.3390/cells10123592 – volume: 77 start-page: 2415 year: 2022 ident: 10.1016/j.ijid.2023.03.011_bib0019 article-title: Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures publication-title: Allergy doi: 10.1111/all.15302 – volume: 369 start-page: 718 year: 2020 ident: 10.1016/j.ijid.2023.03.011_bib0023 article-title: Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients publication-title: Science doi: 10.1126/science.abc6027 – volume: 14 start-page: 898 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0018 article-title: SARS-CoV-2 infection as a trigger of autoimmune response publication-title: Clin Transl Sci doi: 10.1111/cts.12953 – volume: 20 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0025 article-title: An updated advance of autoantibodies in autoimmune diseases publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2020.102743 – volume: 13 start-page: eabh2624 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0009 article-title: Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.abh2624 – ident: 10.1016/j.ijid.2023.03.011_bib0001 – volume: 595 start-page: 283 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0004 article-title: Diverse functional autoantibodies in patients with COVID-19 publication-title: Nature doi: 10.1038/s41586-021-03631-y – volume: 99 start-page: 917 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0008 article-title: Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19 publication-title: Immunol Cell Biol doi: 10.1111/imcb.12495 – volume: 75 start-page: 222 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0030 article-title: Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty? publication-title: J Hepatol doi: 10.1016/j.jhep.2021.04.003 – volume: 22 start-page: 8965 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0017 article-title: Adaptive immunity and the risk of autoreactivity in COVID-19 publication-title: Int J Mol Sci doi: 10.3390/ijms22168965 – volume: 42 start-page: 1111 year: 2022 ident: 10.1016/j.ijid.2023.03.011_bib0012 article-title: Early and rapid identification of COVID-19 patients with neutralizing type I interferon auto-antibodies publication-title: J Clin Immunol doi: 10.1007/s10875-022-01252-2 – volume: 52 start-page: 1120 year: 2022 ident: 10.1016/j.ijid.2023.03.011_bib0011 article-title: Anti-IFN-α/-ω neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity publication-title: Eur J Immunol doi: 10.1002/eji.202249824 – volume: 52 start-page: 910 year: 2020 ident: 10.1016/j.ijid.2023.03.011_bib0005 article-title: Immunology of COVID-19: current state of the science publication-title: Immunity doi: 10.1016/j.immuni.2020.05.002 – volume: 395 start-page: 497 year: 2020 ident: 10.1016/j.ijid.2023.03.011_bib0002 article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China publication-title: Lancet doi: 10.1016/S0140-6736(20)30183-5 – volume: 42 start-page: 459 year: 2022 ident: 10.1016/j.ijid.2023.03.011_bib0026 article-title: Autoantibodies neutralizing Type I interferons in 20% of COVID-19 deaths in a French hospital publication-title: J Clin Immunol doi: 10.1007/s10875-021-01203-3 – volume: 10 start-page: e1327 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0016 article-title: Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients publication-title: Clin Transl Immunology doi: 10.1002/cti2.1327 – volume: 19 start-page: 141 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0003 article-title: Characteristics of SARS-CoV-2 and COVID-19 publication-title: Nat Rev Microbiol doi: 10.1038/s41579-020-00459-7 – volume: 131 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0024 article-title: Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1 publication-title: J Clin Invest doi: 10.1172/JCI150867 – volume: 370 start-page: eabd4585 year: 2020 ident: 10.1016/j.ijid.2023.03.011_bib0007 article-title: Autoantibodies against type I IFNs in patients with life-threatening COVID-19 publication-title: Science doi: 10.1126/science.abd4585 – volume: 8 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0014 article-title: Type-I interferon autoantibodies are detected in those with critical COVID-19, including a young female patient publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofab466.649 – volume: 139 start-page: 783 year: 2020 ident: 10.1016/j.ijid.2023.03.011_bib0020 article-title: Autoantibodies against cytokines: phenocopies of primary immunodeficiencies? publication-title: Hum Genet doi: 10.1007/s00439-020-02180-0 – volume: 4 start-page: 235 year: 2016 ident: 10.1016/j.ijid.2023.03.011_bib0021 article-title: IL-6-specific autoantibodies among APECED and thymoma patients publication-title: Immun Inflamm Dis doi: 10.1002/iid3.109 – volume: 75 start-page: e1192 year: 2022 ident: 10.1016/j.ijid.2023.03.011_bib0027 article-title: Temporal dynamics of anti-type 1 interferon autoantibodies in patients with coronavirus disease 2019 publication-title: Clin Infect Dis doi: 10.1093/cid/ciab1002 – volume: 6 start-page: eabl4340 year: 2021 ident: 10.1016/j.ijid.2023.03.011_bib0015 article-title: Autoantibodies neutralizing type I IFNs are present in ∼4% of uninfected individuals over 70 years old and account for ∼20% of COVID-19 deaths publication-title: Sci Immunol doi: 10.1126/sciimmunol.abl4340 – volume: 42 start-page: 1360 year: 2022 ident: 10.1016/j.ijid.2023.03.011_bib0013 article-title: Neutralizing Type I interferon autoantibodies in Japanese patients with severe COVID-19 publication-title: J Clin Immunol doi: 10.1007/s10875-022-01308-3 – volume: 61 start-page: 78 year: 2015 ident: 10.1016/j.ijid.2023.03.011_bib0010 article-title: Prevalence of suicide attempts among Chinese adolescents: a meta-analysis of cross-sectional studies publication-title: Compr Psychiatry doi: 10.1016/j.comppsych.2015.05.001 |
| SSID | ssj0004668 |
| Score | 2.453771 |
| SecondaryResourceType | review_article |
| Snippet | •COVID-19 was found to be associated with autoantibodies against type I interferons (IFNs).•The most common subtypes were anti-IFN-α (89%) and anti-IFN-ω... In this study, we aimed to study the rate of autoantibodies against type I interferons (IFNs) in patients with COVID-19 and analyze its dependence on severity... Objectives: In this study, we aimed to study the rate of autoantibodies against type I interferons (IFNs) in patients with COVID-19 and analyze its dependence... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 147 |
| SubjectTerms | Anti-type-I-IFN-autoantibodies Autoantibodies COVID-19 Female Humans Interferon Type I Interferon-alpha Interferons Male Meta-analysis SARS-CoV-2 |
| SummonAdditionalLinks | – databaseName: ScienceDirect Free & Delayed Access Titles dbid: IXB link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELemPSAkhMb4Kl8yEm8oahx_JOGtK0wb0uABhvpm2Y49MkE6den_z13slAWkISH1IXXsNvFd7i6--_1MyBtMpvkyuKxRzmUiKJOBlhh4a1XcM6OsVYgdPvukTs7Fx5Vc7ZHliIXBsspk-6NNH6x1apmn2Zxfte38CwPfVZcM_Fs-8LKDHUZUKYL4Vkc3sJERDgedM-ydgDOxxqu9bJEttOAD0SljE-c0cPhPfNTfMeifpZQ3fNPxAbmfgkq6iNf9gOz57pDcOUtp80NyLy7O0Yg5ekjCYtuvYUpbu8YiQmouTAthIsX1WHpKkUJiE_wGFBKO6fLzt9P3GavpWLjVvaML-psCmkb4CzVdQ3_63mQmEZ08IufHH74uT7K04ULmZMn7rAouhNwVwdhcNY0SplLOCykMhCUFLyG6sBIiyiIPRtbMWFfngbmy8dAgZM0fk_1u3fmnhBbCgmAaeJ8rrAhBWlGpWtVVyaXFvT1mhI0zrV1iI8dNMX7osezsUqN0NEpH5_BhbEbe7sZcRS6OW3sfoQB3PZFHe2hYby50UiTtBHemABtvIVZBELCslWPS5sHWxnIzI3wUvx6hqmBc4YfaW_9a7kZNlPmf416PGqbhKcfUjen8enuti7JSEBpLnLgnUeN2N8ZxgUOKckaqiS5O7nx6pmu_D0zimNzBvPmz_7zg5-QufosFoC_Ifr_Z-pcQpPX21fAU_gIUSzlZ priority: 102 providerName: Elsevier |
| Title | Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1201971223000875 https://dx.doi.org/10.1016/j.ijid.2023.03.011 https://www.ncbi.nlm.nih.gov/pubmed/36907547 https://www.proquest.com/docview/2786511534 https://pubmed.ncbi.nlm.nih.gov/PMC10005838 https://doaj.org/article/c43ca2addb0244069596c15b0fb9ab3a |
| Volume | 130 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagB4SEEJTX8qiMxA0F4viRmNu2peqCCheK9mbZjg2pIFtts1d-OzNxErogtRekKIqcOJHH48xnz8xnQl6hMy2U0We18j4TUdkMtMTCrFXxwKxyTmHu8MkndXwqPizl8tJWXxgTluiBk-DeesG9LWAUOrAmmKYptfJMujw6bR3voVGu83EyNWVEpiQ4MG-ZLlkxpMukyK7mrEGO0IL39KaMbZmknrl_yzL9izz_DqC8ZJGO7pG7A5Sk89SE--RGaHfJrZPBWb5L7qQlOZoyjR6QON90KxBk41YYOkjtN9sAOKS4CksXFIkj1jGsQQ3hmh58_ro4zJimY7hW-47O6R_iZ5qSXqhta_ozdDazA73JQ3J69P7LwXE2bLOQeVnyLquijzH3RbQuV3WthK2UD0IKC2Ck4CVgCicBRxZ5tFIz67zOI_NlHaBASM0fkZ121YYnhBbCAdyoYRZXOBGjdKJSWumq5NLhjh4zwkZJGz9wkONWGD_MGGx2ZrB3DPaOyeFgbEZeT3XOEwPHlU_vYwdOTyJ7dl8AOmUGnTLX6dSM8LH7zZigCr9UeFFz5aflVGuALwmWXFvv5ahhBsY2OmxsG1abC1OUlQJALFFwj5PGTQ3juKwhRTkj1ZYubrV8-07bfO_5w9Glg97yp_9DVs_IbWxLigF9Tna69Sa8AJzWuT1y880vBufDxce9fnjCebHc_w1nyjy1 |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGkAAJIRhf5dNIvKHQOLGdhLdSmFpYxwMb2ptlO_HIBMlU0lf-du5ipywgDQkpD5Vjp4nvcnfx3e9nQl5iMq3KnI1KaW3EndQRaImGr1aZVkxLYyRih1eHcnHMP5yIkx0yH7AwWFYZbL-36b21Di3TMJvT87qefmbgu4qMgX-Le172K-Qqx20OQKlf_2QXwJEeDwe9I-wekDO-yKs-q5EuNEl7plPGRt6pJ_EfOam_g9A_aykvOKf92-RWiCrpzN_4HbJTNXvk2irkzffITb86Rz3o6C5xs03XwpzWpsUqQqpPdQ1xIsUFWbqkyCGxdtUaNBJ-0_mnL8t3ESvoULnVvKEz-psDmnr8C9VNSb9XnY50YDq5R4733x_NF1HYcSGyIku7KHfWudgmTptYlqXkOpe24oJriEuSNIPwwggIKZPYaVEwbWwRO2azsoIGLor0Ptlt2qZ6SGjCDUimhA-6xHDnhOG5LGSRZ6kwuLnHhLBhppUNdOS4K8Y3NdSdnSmUjkLpqBgOxibk1XbMuSfjuLT3WxTgticSafcN7fpUBU1SlqdWJ2DkDQQriAIWhbRMmNiZQptUT0g6iF8NWFWwrnCh-tK_FttRI23-57gXg4YpeM0xd6Obqt38UEmWS4iNBU7cA69x2wdLcYVD8GxC8pEujp58fKapv_ZU4pjdwcT5o_-84efk-uJodaAOlocfH5MbeMZXgz4hu916Uz2FiK0zz_o38hedEDxm |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Autoantibodies+against+type+I+interferons+in+COVID-19+infection%3A+A+systematic+review+and+meta-analysis&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Wang%2C+Xi&rft.au=Tang%2C+Qi&rft.au=Li%2C+Hongmei&rft.au=Jiang%2C+Honglin&rft.date=2023-05-01&rft.pub=Elsevier+Ltd&rft.issn=1201-9712&rft.volume=130&rft.spage=147&rft.epage=152&rft_id=info:doi/10.1016%2Fj.ijid.2023.03.011&rft.externalDocID=S1201971223000875 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon |